IC
NRIX icon

Ikarian Capital’s Nurix Therapeutics NRIX Stock Holding History

Ikarian Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34,985
Closed -$659K – 200
2024
Q4 		$659K Sell
34,985
-225,015
-87% -$5.16M 0.09% 121
2024
Q3 		$5.84M Sell
260,000
-180,500
-41% -$4.09M 0.81% 30
2024
Q2 		$9.19M Buy
440,500
+140,500
+47% +$2.19M 1.6% 19
2024
Q1 		$4.41M Buy
+300,000
New +$3.23M 0.48% 59

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital's NRIX Position: Q1 2025 in Review

Ikarian Capital sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 34,985 shares — an estimated $659K sold.

Ikarian Capital first reported a position in NRIX in Q1 2024 and held it in 4 quarters. The position peaked at $9.19M in Q2 2024. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • Ikarian Capital reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 34,985 Nurix Therapeutics shares in Q1 2025, an estimated $659K.
  • Ikarian Capital first reported a position in Nurix Therapeutics in Q1 2024 and held it in 4 quarters.
  • Ikarian Capital's Nurix Therapeutics position peaked at $9.19M in Q2 2024.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.